55 glioblastomas. Unsupervised clustering of DNA methylation patterns revealed two main groups correlated with IDH status: Cpg island methylator phenotype (CIMP) positive (77.5 %) or negative (22.5 %). CIMP pos (IDH mutant) tumors showed a further separation based on copy-number status of chromosome arms 1p and 19q. CIMP neg (IDH wild type) tumors showed hallmark copy-number alterations of glioblastomas, and clustered together with CIMP neg glioblastomas without forming separate groups based on WHO grade. Notably, there was no molecular evidence for a distinct biological entity representing anaplastic oligoastrocytoma. Tumor classification based on CIMP and 1p/19q status was significantly associated with survival, allowing a better prediction of outcome than the current histopathological classification: patients with CIMP pos tumors with 1p/19q codeletion (CIMP-codel) had the best prognosis, followed by patients with CIMP pos tumors but intact 1p/19q status (CIMP-non-codel). Patients with CIMP neg anaplastic
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Introduction
Anaplastic gliomas of World Health Organization (WHO) grade III comprise a common primary CNS tumor in adults. They are histologically subdivided into anaplastic astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas according to morphological criteria [16] . While this histological classification has prognostic value [28] , it is prone to high interobserver variation, especially not only for anaplastic oligoastrocytomas, but also for the differentiation between anaplastic glioma and glioblastoma (WHO grade IV) [13] .
In recent years, large-scale genomic and epigenomic studies have greatly increased our insight into the biology of malignant gliomas, identifying key alterations and molecular groups [4, 8, 23, 26] which may complement the WHO classification. The discovery of a prognostically favorable point mutation in isocitrate dehydrogenase 1 (IDH1) codon 132 [19] , resulting in a neomorphic enzymatic capacity to produce 2-hydroxyglutarate from α-ketoglutarate, has considerably changed the understanding of glioma biology [27] . IDH1 (and less frequently IDH2) mutations are rare (~5 %) in primary glioblastomas, but are found in the majority of secondary glioblastomas as well as diffuse (WHO grade II) and anaplastic gliomas, especially in oligodendrogliomas [34] . Patients with IDH mutant glioblastoma have a better prognosis than IDH wild-type anaplastic astrocytoma patients [9] . The IDH mutation causes epigenetic remodeling [25] , resulting in a Cpg island methylator phenotype (CIMP) [18] . Indeed, gliomas across histological groups with an IDH mutation carry similar epigenetic profiles [6] . This and other studies [14] suggest that IDH mutant gliomas form a biologically distinct molecular group from their wild-type counterparts. This notion is supported by the finding that methylation of the promoter of O
6
-methylguanine DNA-methyltransferase (MGMT) is merely prognostic in IDH mutant anaplastic gliomas, whereas it is predictive for response to alkylating chemotherapy in IDH wild-type gliomas [29, 31] .
Besides IDH, it has been known for some time that patients with tumors harboring 1p/19q codeletion have a better prognosis [22] . When two phase III trials reported their long-term follow-up, both demonstrating an overall survival benefit from combined treatment with radiotherapy and procarbazine, CCNU and vincristine (PCV) chemotherapy mainly in patients with 1p/19q codeleted tumors, the 1p/19q codeletion gained predictive properties [2, 5] . Mutations of the homolog of the Drosophila gene capicua (CIC) on chromosome 19q and far-upstream element binding protein 1 (FUBP1) on 1p have been identified as potential mechanisms involved in the biology of 1p/19q codeleted gliomas [3] . gene expression clustering plus IDH1 and 1p/19q status revealed molecular groups with prognostic value among oligodendroglial tumors [7] .
Mutually exclusive mutations affecting telomerase reverse transcriptase (TERT) and alpha-thalassemia/mental retardation syndrome X-linked (ATRX) have been detected in malignant gliomas [11, 21] . Two point mutations in the promoter of TERT (C228 and C250) resulting in higher TERT mrNA expression were discovered with high frequency in oligodendrogliomas (usually co-occurring with 1p/19q codeletion) and primary glioblastomas. Alternative lengthening of telomeres (AlT) is another, telomerase-independent mechanism of telomere maintenance. ATRX mutations, usually leading to reduced or absent ATrX protein [15] , have been linked to AlT [10] . Consequently, loss of ATrX expression predominantly occurs in astrocytomas and mixed oligoastrocytomas without 1p/19q codeletion (i.e., TERT wild-type tumors) and seems to identify a prognostically more favorable molecular group among anaplastic astrocytoma patients [32] .
genome-wide sequencing data in 284 glioblastoma samples from the TCgA consortium showed that roughly 50 % harbored at least one, usually mutually exclusive somatic mutation in genes functionally linked to chromatin organization, such as IDH1/2, SETD2, EZH2, the HDAC family or ATRX [4] . Analysis of genome-wide DNA methylation patterns revealed distinct molecular groups of glioblastoma associated with defined hotspot mutations (IDH and H3F3A, respectively) or common genomic aberrations like EGFR amplifications [24] .
In contrast to glioblastomas, anaplastic gliomas have been analyzed less comprehensively [7, 17] . Here, the feasibility and prognostic value of a molecular classification of anaplastic gliomas based on epigenetic and copy-number analysis is investigated.
Materials and methods

Patients and tumor samples
Primary tumor samples of anaplastic gliomas for DNA methylation analysis (n = 228) were collected at the Heidelberg University Hospital (Heidelberg, germany, n = 113) and from the NOA-04 trial (n = 115) [28] .
DNA methylation profiling
For genome-wide assessment of DNA methylation patterns, tumor samples were subjected to microarray analyses at the genomics and Proteomics Core Facility of the german Cancer research Center (DKFZ) using the Infinium HumanMethylation450 BeadChip (Illumina, San Diego, CA).
The following filtering criteria were applied: removal of probes targeting the X and Y chromosomes (n = 11,551), removal of probes containing a single-nucleotide polymorphism (dbSNP132 Common) within five base pairs of and including the targeted Cpg site (n = 24,536), and probes not mapping uniquely to the human reference genome (hg19) allowing for one mismatch (n = 9,993). In total, 438,370 probes were kept for analysis.
Statistical analysis of DNA methylation
For unsupervised hierarchical clustering, we selected the 10,000 most variable methylated probes that showed highest median absolute deviation (MAD) across beta values. Pairwise similarity between cases was calculated using euclidean distance and hierarchical clustering was performed using Ward's linkage method. To cluster Cpg probes, we applied hierarchical clustering using one-centered Pearson correlation as similarity measure and average linkage as hierarchical clustering method.
To predict MGMT methylation using methylation (M values) of Cpg probes "cg12434587" and "cg12981137", we applied the logistic regression model MgMT-STP27 [1] .
Detection of TERT promoter and ATrX aberrations
Data for TERT promoter hotspot mutations and for loss of ATrX expression [using immunohistochemistry (IHC)] in this patient cohort have been reported before [12, 32] .
Data repository
Data are accessible at geO (http://www.ncbi.nlm.nih. gov/geo/), accession number gSe58218. Additional methylation data of 55 adult glioblastoma samples used for comparison with anaplastic gliomas and six non-neoplastic brain tissue samples used as reference to generate copynumber variation plots are publicly available at geO under the accession number gSe36278.
Statistical analysis of clinical and molecular data
Kaplan-Meier estimator, log-rank test and multivariate Cox regression analyses were used to assess survival differences. Comparisons of binary and categorical patient characteristics between molecular groups were performed by the use of a two-sided Fisher's exact test. Continuous variables were compared using ANOVA and post hoc pairwise comparisons with Holm's multiple testing procedure. Analyses were carried out using Stata IC version 12.1 (StataCorp lP, College Station, TX, USA) and r version 3.0.2 [20] .
Results
Unsupervised analysis identifies two main clusters of anaplastic gliomas
Unsupervised clustering methods using genome-wide DNA methylation patterns generated from 228 anaplastic gliomas revealed two main clusters, which were closely associated with IDH mutation status ( Fig. 1 ). In the first cluster, consisting of 177 (77.5 %) samples, 156/160 samples with available mutation status harbored an IDH mutation (94 %, IDH status was unavailable for 17 samples). Only 1 out of 35 assessable samples (3 %) in the second cluster (in total 51 tumors, 22.5 %) carried an IDH mutation (IDH status was unavailable for 16 patients). In analogy to similar DNA methylation patterns observed in glioblastoma, we thus refer to the first (hypermethylated) cluster as CIMP pos and to the second cluster as CIMP neg (Supplementary Fig. 1 ). Patients with CIMP pos tumors had significantly longer overall survival than patients with a CIMP neg tumor (log rank p < 0.001; Supplementary  Fig. 2 ). Anaplastic astrocytomas were more frequently CIMP neg (34/93, 36.5 %) than oligodendrogliomas (10/71, 14 %) or oligoastrocytomas (7/64, 11 %; Fisher's exact test p < 0.001, Table 1 ).
The effect of IDH mutation on the methylome is so pronounced that identification of further molecular groups beyond CIMP pos and CIMP neg is challenging when assessing all samples together. We therefore performed an additional analysis using copy-number and methylation data to investigate potential substructures within these two clusters, and also included previously published glioblastomas with known CIMP status [24] . (Fig. 2) . Copy-number analysis revealed that this separation is based on 1p/19q status, as 79/82 samples (96 %) in one cluster had 1p/19q codeletion as opposed to 8/109 (7 %) in the other cluster (Fisher's exact test, p < 0.001). As expected from the distribution of 1p/19q codeletion in anaplastic gliomas, the group with 1p/19q codeletion was significantly enriched for oligodendrogliomas and oligoastrocytomas, as was the group with intact 1p/19q status for astrocytomas (Table 1) . We therefore termed these molecular groups CIMP-codel and CIMPnon-codel, respectively. There was no further subtyping based on histology, e.g., a split between astrocytomas and oligoastrocytomas in the CIMP-non-codel cluster. None of the 14 CIMP pos glioblastomas displayed a 1p/19q codeletion and all clustered with the CIMP-non-codel tumors without forming a separate molecular group. Furthermore, characteristic glioblastoma copy-number alterations (EGFR amplification, gain of chromosome 7, and loss of chromosome 10) were evenly rare in both CIMP pos molecular groups. Homozygous CDKN2A deletion occurred in 13/109 CIMP-non-codel tumors (two glioblastomas, 11 anaplastic gliomas) and in no CIMP-codel tumor. However, the low numbers precluded further statistical analysis of survival differences in the above-mentioned smaller groups.
The biological differences between CIMP-non-codel and CIMP-codel tumors are further evidenced by the distribution of TERT promoter mutations and ATrX expression in the two molecular groups: TERT promoter mutations (C228 and C250) were detected in 57/65 CIMP-codel tumors (88 %), but only in 7/80 in the CIMP-non-codel group (9 %, notably, 6 of these had 1p/19q codeletion).
Conversely, loss of ATrX expression determined by immunohistochemistry was common in the CIMP-non-codel group, where 32/40 tumors (80 %) had lost ATrX expression as opposed to the CIMP-codel group, where only 1/34 tumors with available ATrX status showed this feature. Of note, no tumor (of 86 samples being analyzed both for TERT and ATrX status) displayed both, an ATrX loss and a TERT promoter mutation, consistent with these two pathways of telomere lengthening being mutually exclusive.
Interestingly, of the eight tumors with 1p/19q codeletion that were found in the CIMP-non-codel group by cluster analysis, seven clustered tightly together and had TERT mutations. These tumors stably clustered in the CIMP-noncodel group even when using different similarity measures and linkage methods for the hierarchical clustering, indicating that these tumors, even while carrying 1p/19q codeletion, have a different methylation profile than the majority of the 1p/19q codeleted tumors. By histology, 6/7 of these tumors were diagnosed as anaplastic oligodendroglioma. Assessment of MGMT promoter methylation using the MgMT-STP27 algorithm [1] revealed a high frequency of MGMT promoter methylation in CIMP pos tumors: of 191 tumors, only nine tumors (5 %) were predicted to have an unmethylated MGMT promoter. These nine samples (eight anaplastic gliomas, one glioblastoma) all belonged to the CIMP-non-codel group, while all 82 tumors in the CIMPcodel group were scored as MGMT methylated. Importantly though, as the MgMT-STP27 was trained on glioblastoma DNA samples from fresh frozen tissue its ability to correctly predict the MgMT status of DNA samples coming from FFPe material might be limited (see Supplementary Discussion).
CIMP
neg anaplastic gliomas share copy-number aberrations and methylation profiles with IDH wild-type glioblastomas As with the CIMP pos tumors, we grouped the 51 CIMP neg anaplastic gliomas with 41 glioblastomas with known copynumber and methylation profiles from the study of Sturm et al. [24] . Unsupervised clustering did not separate anaplastic gliomas and glioblastomas into distinct clusters, with tumors of both WHO grades largely mixing (Fig. 3) . Subsets of CIMP neg anaplastic gliomas clustered together with glioblastomas of each of the mesenchymal, rTK I and rTK II groups, respectively. The seeming interposition of the rTK I samples in between rTK II samples is most likely caused by different normal cell amounts and/or hybridization quality and not a real biological difference between the two rTK II clusters. This biological similarity of CIMP neg anaplastic gliomas and glioblastomas based on methylation data is also reflected in the copy-number profiles: hallmark glioblastoma alterations were found at similar frequency in anaplastic gliomas and glioblastomas (Fisher's exact test, p > 0.1 for each Fig. 3) . Furthermore, copy-number aberrations showed typical patterns, for example with EGFR amplifications and CDKN2A deletions occurring mostly in rTK II glioblastomas as well as the anaplastic gliomas clustering with them. MGMT promoter methylation was also found at similar frequency in both WHO grades: 23/51 anaplastic gliomas (45 %) and 18/41 glioblastomas (44 %) were predicted to have a methylated MGMT promoter according to the MGMT-STP27 algorithm. In CIMP neg samples from NOA-04 (n = 24), MGMT status clearly was associated with differences in progression-free survival in the chemotherapy arm, while no such obvious effect was seen in the radiotherapy arm ( Supplementary Fig. 3) . However, the small number of samples in each subgroup precluded further statistical analysis.
Integrated molecular classification is significantly associated with survival
Taken together, these data suggest that anaplastic gliomas can be robustly divided into three main molecular groups based on DNA methylation and copy-number data and independent of histology: CIMP neg tumors, which molecularly resemble glioblastomas, CIMP-non-codel tumors with intact 1p/19q and CIMP-codel tumors with 1p/19q codeletion (Fig. 5) .
Our series of anaplastic gliomas contained 115 samples from the biomarker cohort of the NOA-04 trial, which investigated the optimal sequence of radiotherapy and chemotherapy in patients with newly diagnosed anaplastic gliomas [28] . Baseline patient characteristics of these 115 samples closely resembled those of the entire NOA-04 trial cohort (Supplementary Table 1) , except for an enrichment of patients with tumor resection as opposed to biopsy due to the tissue requirements for DNA methylation analyses. As observed in the entire NOA-04 cohort, both treatment sequences performed very similar (log-rank test, p = 0.94).
Of the 115 samples, 24 were CIMP neg , 48 CIMP-noncodel and 43 CIMP-codel. Time to treatment failure (TTF), the primary endpoint of NOA-04, showed a clear separation of patients based on molecular classification (Fig. 4a) : 326-1,071 days) ]. This was also true for overall survival (Fig. 4b) . As opposed to reference histology (Fig. 4c, d) , this led to a clearer separation of prognostic subgroups. Consequently, in a multivariate Cox regression model including molecular classification, reference histology and age, only molecular classification and age, but not reference histology, were significantly associated with outcome (Table 2 ). To account for potential collinearity between molecular classification and reference histology, we analyzed the prediction error curves for Cox models based on reference histology or molecular classification only or including both. This indicated again a better prediction of survival through the molecular classification as opposed to reference histology and only a small improvement of prediction when including both reference histology and molecular classification ( Supplementary Fig. 4 ).
Discussion
Using DNA methylation profiling and copy-number analysis, we identified three principal molecular groups of anaplastic gliomas in a cohort of 228 samples: CIMP neg tumors, which resemble glioblastomas, CIMP-codel tumors with 1p/19q codeletion as a hallmark genomic alteration and CIMP-non-codel tumors, which lack this copy-number aberration (key characteristics are summarized in Table 1 ); the classification scheme is shown in Fig. 5 . Importantly, this classification not only reflects molecular differences between these groups, but also better translates into clinically relevant survival differences when compared with the WHO classification as evidenced in the biomarker cohort of the NOA-04 trial ( Fig. 4 ; Table 2 ).
The majority of oligoastrocytomas and oligodendrogliomas [34] belonged to the CIMP pos cluster. Based on their epigenome-wide DNA methylation profile, tumors belonging to the CIMP pos cluster can be further subdivided by 1p/19q status (also the first split to occur after CIMP positive vs. negative when looking at all samples; Fig. 1 ) as suggested before for a smaller (n = 46) series of purely oligodendroglial tumors [17] . We termed these clusters CIMP-codel (mainly 1p/19q codeleted with oligodendroglial histology) and CIMP-non-codel (mainly 1p/19q intact and astrocytic). Notably, the 14 CIMP pos glioblastomas included in this analysis all clustered well within the CIMP-non-codel molecular group. On the other hand, CIMP neg (and hence IDH wild type) anaplastic gliomas were molecularly indistinguishable from CIMP neg glioblastomas: hallmark glioblastoma copy-number aberrations were found in comparable frequency in both tumor grades. Consequently, unsupervised clustering did not sort WHO grade III and IV CIMP neg tumors into separate clusters. In contrast, these copy-number aberrations are rare in CIMPpos tumors (of WHO grade III or IV). Thus, anaplastic gliomas and glioblastomas with a given CIMP status are more similar to each other than CIMP pos vs. CIMP neg tumors of a certain histology, strongly supporting the notion that IDH mutant and IDH wild-type tumors are in fact distinct entities [14] .
In our cohort, median overall survival was longer in CIMP neg anaplastic gliomas than in glioblastomas (Supplementary Fig. 5 ). However, the cohort for this comparison is very heterogeneous with respect to treatment and clinical follow-up, including prognostically favorable NOA-04 study patients. longer overall survival for IDH wild-type anaplastic astrocytomas compared to glioblastomas has been reported in another retrospective series [9] . However, in elderly patients with newly diagnosed WHO grade III or IV astrocytomas, which are almost always IDH wild type [33] , there was no survival difference [30] . Since most anaplastic gliomas eventually progress to secondary glioblastomas at recurrence, a survival difference may just reflect that CIMP neg anaplastic gliomas are diagnosed in an earlier stage of tumor development compared to CIMP neg glioblastoma. Another explanation may be yet to be defined groups in the CIMP neg anaplastic gliomas which (1) share a glioblastoma-like clinical course or show (2) a markedly longer survival. For the time being, our findings suggest that WHO grading retains a prognostic role within the group of CIMPneg high-grade gliomas. Histological classification of anaplastic gliomas, in particular of mixed oligoastrocytomas, has considerable interobserver variability [13] . Molecularly, oligoastrocytomas do not form a separate biological entity, as they are evenly distributed between the CIMP-codel and CIMP-non-codel clusters (24 and 33 cases, respectively), while pure oligodendrogliomas and astrocytomas were predominantly sorted in the CIMP-codel or CIMP-non-codel cluster, respectively (Table 1) . Since there is no further subtyping based on histology in either CIMP pos cluster, e.g., a split between astrocytomas and oligoastrocytomas in the CIMPnon-codel cluster, there seems to be no clear biological basis for the diagnosis of an oligoastrocytoma. Mean age at diagnosis significantly differed between all three groups ( Table 1 , p < 0.0001, ANOVA).
With a stringent central histology, NOA-04 demonstrated a clear survival benefit for patients with oligodendrogliomas and oligoastrocytomas compared to astrocytomas, which was also retained in our cohort of 115 NOA-04 patients (Supplementary Table 2 ). This cohort is therefore well suited to compare the clinical significance of this molecular classification of anaplastic gliomas. In a multivariate Cox regression model, histological assessment did not significantly correlate with survival anymore once molecular subtyping was added as a covariate, pointing to a diagnostic superiority of molecular subtyping.
In the long-term follow-up analysis of two large randomized phase III trials, 1p/19q codeletion was concordantly shown to predict benefit from radio-chemotherapy [2, 5] . However, in both trials, several patients with 1p/19q codeletion did not benefit from this intensified treatment. In our classification, while 1p/19 status is clearly the defining feature for the two molecular groups, 8 out of 95 tumors in the CIMP-non-codel group carried 1p/19q codeletion (and TERT mutation). Whether these tumors represent a distinct group is currently unclear. An influence of other factors on the DNA methylation profile such as infiltrating normal (reactive) astrocytes can also not be excluded. Based on this observation, however, it seems possible that these might be the rare 1p/19q codeleted tumors not benefitting from intensified treatment. This hypothesis could be tested in either rTOg-9402 or eOrTC-26951. Furthermore, both trials were designed to include only oligodendroglial tumors, but no astrocytomas, although reference histology revealed a relevant proportion of grade II gliomas, anaplastic astrocytoma and even glioblastoma [13] . While 1p/19q codeletion occurs only infrequently in astrocytomas (three out of 93 anaplastic astrocytomas belonged to the CIMPcodel group), our observation that anaplastic astrocytoma with 1p/19q codeletion molecularly resemble codeleted oligodendroglial tumors supports the notion that this subset should also be treated with combined radio-chemotherapy at initial diagnosis.
In summary, we demonstrate a classification of anaplastic gliomas based on (epi)genome-wide DNA methylation and copy-number profiles, where tumors can be divided into CIMP pos tumors with or without 1p/19q loss, and CIMP neg tumors which closely resemble glioblastomas (and may in fact be true glioblastomas biologically, but diagnosed at an earlier stage of tumor development, for example). This information, together with MGMT status, can be readily obtained from one platform (450 k DNA methylation array), suggesting a possible simplification of routine diagnostic testing for this set of tumors. This biological classification is also significantly associated with outcome: patients with CIMP-codel tumors have the best prognosis, followed by those with CIMP-non-codel tumors and lastly CIMP neg tumors. Defining such groups will allow for a clearer understanding of their pathophysiological drivers, enabling a more rational search for therapeutic targets. The presented molecular classification has the potential to greatly complement the standard histological WHO classification by providing a biologically meaningful and clinically relevant stratification algorithm, and warrants further examination in future clinical trials.
